This professional text is for educational and research purposes only. It does not constitute a recommendation for human use.

What is Reta-Solution?

Reta-Solution is an experimental synthetic peptide that acts as an agonist at three different receptors: GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent insulinotropic peptide), and the glucagon receptor (GCGR). This combination makes it a so-called “triple agonist,” with each of these receptors involved in the regulation of metabolism, energy expenditure, and glucose homeostasis. Reta-Solution is being investigated for the treatment of obesity, metabolic syndrome, and type 2 diabetes. In practice, this means that it is a substance that combines multiple effects at once – it suppresses appetite, supports energy expenditure, and improves metabolic balance.

How does Reta-Solution work?

The mechanism of action of Reta-Solution lies in its ability to activate three important hormonal pathways:

• GLP-1: Reduces appetite, slows gastric emptying, and increases insulin secretion.
• GIP: Enhances the response of pancreatic beta cells to glucose and affects fat storage.
• Glucagon receptor: Increases energy expenditure, stimulates lipolysis, and affects glucose metabolism.

Researched effects and interesting facts

• Body weight loss of more than 24% over 48 weeks in some phases of clinical trials.
• Decreased appetite after the first application.
• Improving insulin sensitivity and reducing fasting glucose levels.
• Protective effects on cardiometabolic markers – blood pressure, triglycerides, CRP.
• Potential for use also in the field of neuroendocrine disorders.

Dosage in studies

The data below is derived from clinical and preclinical research. It is not a recommended dosage.

• Dose: 0.5–12 mg per week
• Administration form: subcutaneous (under the skin) injection
• Frequency: 1× per week
• Duration: 8–48 weeks depending on the study

Possible side effects

• Nausea, especially during the first few weeks.
• Constipation or diarrhea.
• Temporary loss of appetite and fatigue.
• Irritation at the injection site (in the subcutaneous form).

Resources

• Jastreboff et al., 2023 - NEJM, Reta-Solution Phase 2 Obesity Study
• ClinicalTrials.gov - NCT04881760, NCT05386027
• Lilly Research, 2022 - Internal Reports

All information provided is for informational purposes only and is based on available scientific studies. The product is not approved for human use.